Sylvester Comprehensive Cancer Center, University of Miami | Strategic Alliance Partners

August 30, 2021

Dr. Sekeres discusses the current unmet needs of patients with higher-risk myelodysplastic syndromes receiving hypomethylating agents, the potential utility of novel combinations in development, and the incorporation of other end points beyond overall survival in clinical trials.

August 12, 2021

Mikkael A. Sekeres, MD, discusses the goal of transfusion independence in higher-risk myelodysplastic syndromes.

August 03, 2021

C. Ola Landgren, MD, PhD, discusses novel therapeutic approaches that are generating excitement in multiple myeloma.

June 26, 2021

Gilberto Lopes, MD, discusses the latest developments made in the treatment of patients with non–small cell lung cancer whose tumors harbor genetic alterations and the clinical implications of recent regulatory approvals.

June 21, 2021

C. Ola Landgren, MD, PhD, focuses on the cellular- and immunotherapy-based elements from the event and where these modern therapies optimally fit in multiple myeloma.

June 17, 2021

C. Ola Landgren, MD, PhD, discusses key safety considerations with a novel carfilzomib quadruplet regimen in patients with newly diagnosed multiple myeloma, the clinical implications of the phase 2 MANHATTAN trial, and next steps for this research.

June 17, 2021

Quadruplet regimens, such as those with daratumumab, are on the rise in the frontline treatment of patients with multiple myeloma, and the FDA approval of the first BCMA-targeted CAR T-cell therapy idecabtagene vicleucel represents the monumental advance made in the relapsed/refractory setting.

June 16, 2021

C. Ola Landgren, MD, PhD, discusses important research efforts that led to the launch of the phase 2 MANHATTAN trial, the results achieved with the weekly carfilzomib quadruplet regimen in patients with newly diagnosed multiple myeloma, and the potential for this approach irrespective of transplant eligibility status.

May 31, 2021

Dr. Landgren discusses the potential of a quadruplet regimen comprised of carfilzomib, lenalidomide, dexamethasone, and daratumumab in the treatment of patients with newly diagnosed multiple myeloma.

May 20, 2021

Dickran G. Kazandjian, MD, discusses the potential utility of bispecific T-cell engagers in relapsed/refractory multiple myeloma.

May 13, 2021

Ola Landgren, MD, PhD, discusses the clinical impact of the 4-drug combination of carfilzomib, lenalidomide, dexamethasone, and daratumumab in patients with multiple myeloma.

May 12, 2021

Ola Landgren, MD, PhD, and Francesco Maura, MD, discuss their research with whole-genome sequencing in patients with precursor conditions, and spotlight next steps for research.

May 11, 2021

The quadruplet combination comprised of carfilzomib, lenalidomide, dexamethasone, and daratumumab was linked with high rates of minimal residual disease negativity and progression-free survival in patients with newly diagnosed multiple myeloma.

May 10, 2021

Dickran G. Kazandjian, MD, discusses novel therapeutic targets in multiple myeloma.

May 03, 2021

Francesco Maura, MD, discusses the challenges of whole-genome sequencing in multiple myeloma.

April 28, 2021

Dickran G. Kazandjian, MD, discusses the rationale to evaluate retreatment with BCMA-directed therapy in multiple myeloma.

April 09, 2021

Jonathan C. Trent, MD, PhD, discusses the role of avapritinib in PDGFRA exon 18–positive gastrointestinal stromal tumor.

April 08, 2021

Encouraging efficacy data for ripretinib as a later-line therapy for patients with advanced gastrointestinal stromal tumor have investigators hypothesizing new approaches to derive even greater benefit with the agent.

March 19, 2021

Jonathan C. Trent, MD, PhD, discusses the utility of circulating tumor DNA to understand primary driver mutations in gastrointestinal stromal tumor.

March 18, 2021

Sophia George, PhD, discusses actionable pathogenic variants in patients with breast cancer who live in the Caribbean.